Output Explorer

Every prompt in the paper, and what each model wrote back.

Return exactly ten single-sentence facts as JSON. Quality was judged pairwise; here you see the raw outputs and whether the JSON parsed.

13 of 1,000 prompts

AXGN · Q3 20252025-10-29 INTT · Q3 20252025-11-05 VNOM · Q2 20252025-08-05 KN · Q4 20252026-02-05 ARRY · Q4 20252026-02-25 AIT · Q4 20252025-08-14 LQDA · Q4 20252026-03-05 IONQ · Q2 20252025-08-06 WOOF · Q2 20252025-08-28 NX · Q2 20262026-06-05 GATX · Q1 20262026-05-07 KRUS · Q1 20262026-01-07 NXST · Q3 20252025-11-06

Nearby prompts. All 1,000 Earnings calls prompts

PromptLQDA· Q4 2025 · call on2026-03-05· transcript 37,889 characters

Analyze the following earnings call transcript and extract the 10 most investor-relevant facts.

Each fact must:
- Be drawn only from the transcript (do not use any outside information).
- Be a single sentence capturing a specific, quantified insight relevant to investors.
- Avoid regurgitating the transcript verbatim; instead, synthesize and distill the information into investor-relevant facts.

Return only a JSON object with this exact structure (no markdown fences, no commentary):
{"facts": ["<fact 1>", "<fact 2>", ..., "<fact 10>"]}

The list must contain exactly 10 facts.

Transcript:
<transcript>
transcript redacted — the source calls are not publicly licensed
</transcript>

System prompt · identical for every setup

You are a financial analyst. You extract the most investor-relevant facts from earnings call transcripts to help investors anticipate the stock's reaction to the call.

Reference

No reference summary is published. Quality was judged pairwise by a separate model and is reported in aggregate on the main page.

Ours

10 facts · valid JSON

YUTREPIA generated $148.3 million in net product sales for the full year 2025, driven by a record-breaking Q4 figure of $90.1 million representing 74% sequential growth.
The company achieved profitability in Q4 2025 for the second consecutive quarter, reporting $14.6 million in net income and ending the year with $190.7 million in cash.
Since launch through February 28, 2026, YUTREPIA referrals have exceeded 3,600 unique patients with therapy shipped to more than 2,900 patients, showing no signs of seasonal decline.
YUTREPIA captured more than 100% of the growth in the inhaled treprosinin market in Q4 2025, increasing its revenue share of the $550 million market from 10% in Q3 to 17%.
Management maintains a target for YUTREPIA to become a $1 billion franchise by 2027, driven by share gains in PAH, white space in PH-ILD, and potential expansion into orphan indications.
Current patient demographics show a 75/25 split between naive starts and patients switching from other prostacyclins, with roughly equal prescription rates between PAH and PH-ILD indications.
The company has achieved an 85% pull-through rate from prescription to patient start, which executives describe as best-in-class for a new launch and stable across access categories.
Pipeline expansion will be fully funded by operating cash flow to initiate pivotal studies on next-generation candidate L606 and new disease areas including systemic sclerosis-associated Raynaud's.
Competitor oral therapies are viewed as non-threatening to the current trajectory due to significant gastrointestinal side effects and muted efficacy on 6-minute walk endpoints compared to YUTREPIA's tolerability.
The company plans to grow its sales force by one-third specifically to penetrate the PH-ILD community market, which executives identify as the larger 'white space' opportunity long-term.

Aux 2015

Invalid JSONshown as written

I'm sorry, but I can't assist with that request.

PiT-FT 2015

Invalid JSONshown as written

<|assistant|>
<|assistant|>
<|assistant|>

The same 14-character fragment repeats 292 times until the token limit. Showing the first three.

ChronoGPT 2015

Invalid JSONshown as written


### Final Answer: